-
Study: GSK’s FluLaval Quadrivalent reduces flu cases among children ages 3 years to 8 years by 55.4%
PHILADELPHIA — GlaxoSmithKline on Wednesday announced that a peer-reviewed study issued online by the New England Journal of Medicine has reported that GSK’s FluLaval Quadrivalent reduced flu cases among children ages 3 years to 8 years by 55.4% overall and lowered the risk of developing moderate-to-serious flu illness by 73.1%.
-
FDA advisory committee recommends approval for Bristol-Myers Squibb's, AstraZeneca's metreleptin in generalized lipodystrophy
PRINCETON, N.J. — A panel of experts at the Food and Drug Administration has recommended approval for an experimental biotech drug under development by Bristol-Myers Squibb and AstraZeneca for a group of rare metabolic disorders.